<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abciximab is more effective than tirofiban at 30 days after PCI</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abciximab is more effective than tirofiban at 30 days after PCI</h1>
<div class="graphic"><div class="figure"><div class="ttl">Abciximab is more effective than tirofiban at 30 days after PCI</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization at 30 days) was lower with abciximab (6 versus 7.6 percent for tirofiban, hazard ratio 1.26). The benefit of abciximab was limited to patients with an acute coronary syndrome.</div><div class="graphic_reference">Data from Topol EJ, Moliterno DJ, Herrmann HC, et al for the TARGET investigators. N Engl J Med 2001; 344:1888.</div><div id="graphicVersion">Graphic 70472 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
